Business
Kohl’s
(Photo by Scott Olson/Getty Images)
Sale

Turns out the activist investors didn’t have the secret sauce for Kohl’s

Nate Becker

Kohl’s stock tanked today after it slashed guidance and doled out a lackluster earnings report. That’s surely not pleasing to any of its investors, but it’s an especially bad look for the activists who started shaking things up at the department store company in 2021.

Back then, Kohl’s struck a deal with a handful of activist investors you probably haven’t heard of (Macellum Advisors, Ancora Holdings, Legion Partners, and 4010 Capital) after they agitated for change. The company agreed to add two of their hand-picked directors to the board, as well as a mutually agreed upon third director. (One of the activists’ picks retired just this month.)

In mid-2022, Kohl’s tried to sell itself to the owner of Vitamin Shoppe for around $8 billion, but the talks fell apart. Then in late 2022, Ancora ramped up the pressure, seeking even more directors and trying to remove Kohl’s CEO, Michelle Gass, who soon left to become the CEO-in-waiting at Levi Strauss. Tom Kingsbury, one of the directors the activists had picked, took over as Kohl’s CEO. 

One of the main concerns the activists had from the start was that Kohl’s wasn’t moving fast enough to address stagnant sales and declining operating margins, The Wall Street Journal reported at the time

Turns out, that’s still a problem. In today’s earnings report, revenue and profit fell short of analysts’ estimates, with overall sales sliding 5.3% and same-store sales dropping 4.4%. Operating margin dropped to 1.4% from 2.9%, and the company lowered its operating margin forecast for the year. 

In response, the stock dropped 23% on Thursday. That put it at $21.02, which is about 60% lower than where it was trading when reports of the activists’ presence surfaced. 

Of course, it’s tough to pinpoint prices at which activist investors buy and sell stocks, so it’s possible they made money on their investments. The firms combined to control about 9.5% of Kohl’s in 2021, according to reports at the time. Bloomberg data show Ancora owned about 1.4% of the stock at the end of the first quarter this year. Macellum, meanwhile, slashed its position dramatically in the first quarter and owned just 0.2% as of quarter end. Legion and 4010 exited the stock by the end of 2021 and middle of 2022, respectively. 

But two of their three picks still sit on the board — one of them at the helm of the company — and their ideas certainly didn’t light a fire under the stock price for the long term, or in some cases, couldn’t gain traction with shareholders.

In Kohl’s earnings presentation Thursday, Kingsbury said the results “did not meet our expectations and are not reflective of the direction we are heading with our strategic initiatives.”

Gass, Kohl’s former CEO, may get the last laugh: She took over running Levi’s from longtime CEO Chip Bergh in January, and the stock is up 44% so far this year. Kohl’s, meanwhile, is down 25%.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.